My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 311

    1.

    Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

    Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A.

    Diabetes Care. 2007 Feb;30(2):217-23. Erratum in: Diabetes Care. 2007 May;30(5):1330. PMID: 17259484 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.

    Pan C, Yang W, Barona JP, Wang Y, Niggli M, Mohideen P, Wang Y, Foley JE.

    Diabet Med. 2008 Apr;25(4):435-41. Epub 2008 Mar 13.PMID: 18341596 [PubMed - indexed for MEDLINE]Related articles

    3.

    Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study.

    Bolli G, Dotta F, Rochotte E, Cohen SE.

    Diabetes Obes Metab. 2008 Jan;10(1):82-90. Epub 2007 Nov 22.PMID: 18034842 [PubMed - indexed for MEDLINE]Related articles

    4.

    Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

    Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S.

    Diabetes Obes Metab. 2007 Mar;9(2):166-74.PMID: 17300592 [PubMed - indexed for MEDLINE]Related articles

    5.

    Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

    Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ.

    Diabetes Care. 2007 Apr;30(4):890-5. Epub 2007 Feb 2.PMID: 17277036 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.

    Pi-Sunyer FX, Schweizer A, Mills D, Dejager S.

    Diabetes Res Clin Pract. 2007 Apr;76(1):132-8. Epub 2007 Jan 12.PMID: 17223217 [PubMed - indexed for MEDLINE]Related articles

    7.

    Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy.

    Pratley RE, Rosenstock J, Pi-Sunyer FX, Banerji MA, Schweizer A, Couturier A, Dejager S.

    Diabetes Care. 2007 Dec;30(12):3017-22. Epub 2007 Sep 18.PMID: 17878242 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.

    Dejager S, Razac S, Foley JE, Schweizer A.

    Horm Metab Res. 2007 Mar;39(3):218-23.PMID: 17373638 [PubMed - indexed for MEDLINE]Related articles

    9.

    Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin.

    Göke B, Hershon K, Kerr D, Calle Pascual A, Schweizer A, Foley J, Shao Q, Dejager S.

    Horm Metab Res. 2008 Dec;40(12):892-5. Epub 2008 Aug 22.PMID: 18726829 [PubMed - indexed for MEDLINE]Related articles

    10.

    Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.

    Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjörnsdottir S, Camisasca RP, Couturier A, Baron MA.

    Diabetes Obes Metab. 2008 Nov;10(11):1047-56. Epub 2008 Feb 18.PMID: 18284434 [PubMed - indexed for MEDLINE]Related articles

    11.

    Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

    Rosenstock J, Kim SW, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S.

    Diabetes Obes Metab. 2007 Mar;9(2):175-85.PMID: 17300593 [PubMed - indexed for MEDLINE]Related articles

    12.

    Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes.

    Schweizer A, Couturier A, Foley JE, Dejager S.

    Diabet Med. 2007 Sep;24(9):955-61. Epub 2007 May 17.PMID: 17509069 [PubMed - indexed for MEDLINE]Related articles

    13.

    Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.

    Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Jauffret S, Foley JE.

    Diabetes Obes Metab. 2008 Aug;10(8):675-82. Epub 2007 Nov 22.PMID: 18248490 [PubMed - indexed for MEDLINE]Related articles

    14.

    Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.

    Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager S.

    Diabetes Obes Metab. 2009 Feb;11(2):157-66.PMID: 19125777 [PubMed - indexed for MEDLINE]Related articles

    15.

    A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.

    Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR.

    Clin Ther. 2007 Sep;29(9):1900-14.PMID: 18035190 [PubMed - indexed for MEDLINE]Related articles

    16.

    Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

    Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

    Diabetes Care. 2006 Mar;29(3):554-9.PMID: 16505505 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

    Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

    18.

    Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes.

    Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S.

    Diabetologia. 2007 Jun;50(6):1148-55. Epub 2007 Mar 27.PMID: 17387446 [PubMed - indexed for MEDLINE]Related articles

    19.

    Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.

    Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A.

    Diabetes Obes Metab. 2006 Nov;8(6):650-60.PMID: 17026489 [PubMed - indexed for MEDLINE]Related articles

    20.

    Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.

    Bailey CJ, Bagdonas A, Rubes J, McMorn SO, Donaldson J, Biswas N, Stewart MW.

    Clin Ther. 2005 Oct;27(10):1548-61.PMID: 16330291 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity